Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| hormonal refractory prostate cancer |
|
Marshall Edwards Inc. - Phenoxodiol However, the majority of cases of prostate cancer eventually become independent of testosterone, at which time they are known as hormone-refractory prostate Hormone-refractory prostate cancer - Hutchinson encyclopedia Hutchinson encyclopedia article about Hormone-refractory prostate cancer. Hormone-refractory prostate cancer. Information about Hormone-refractory prostate UroToday - AUA 2006 - Hormone Refractory Prostate Cancer Presented Breaking Urology news written by Urologists for Urologists. Global leaders in Urology provide key conference report coverage and daily articles on top Blackwell Synergy - BJU Int, OnlineEarly Articles (Full Text) Nishimura K, Nonomura N, Yasunaga Y et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 89: 2570Á“6 Taxanes in Hormone-Refractory Prostate Cancer taxel in patients with hormone refractory prostate cancer. (HRPC): long term results. Proc ASCO. 1999;18:1206. 8. Hudes GR, Nathan F, Khater C, et al. BA - Chemotherapy For Hormone Refractory Prostate Cancer (HRPC) As is the case of many other prostate cancer patients, in the past three years I have exhausted six hormonal ablation therapies and in May/June 2000 bone Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer | Strategic Report | BUY NOW from Piribo.com - á¸8000 / $16114 / Á‚¬11789 - Currently Metastatic And Hormone Refractory Prostate cancer Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Cleveland BioLabs, Inc. (Nasdaq: CBLI; BSE: CFB), announced today that its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory 2006 Prostate Cancer Symposium - Session On Hormone Refractory An Abstract Presentation on the Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Hormone Refractory Prostate Hormone Refractory Prostate Cancer prostate cancer hormone only temporarily stops prostate cancer before hormone refractory prostate cancer begins. Chemotherapy for hormone-refractory prostate cancer Mike Shelley, Craig Harrison, Bernadette Coles, John Staffurth, Timothy J Wilt, Malcolm D Mason. Chemotherapy for hormone-refractory prostate cancer. Prostate cancer (hormone-refractory) - docetaxel Prostate cancer (hormone-refractory) - docetaxel. Docetaxel for the treatment of hormone refractory prostate cancer. Status:, History Prostate Microreviews - Clinical, Hormone Refractory Prostate Oh WK, Kantoff PW, Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol. 160; 1220-1229, 1998. Prostate cancer (hormone-refractory) - docetaxel Docetaxel for the treatment of hormone refractory prostate cancer TA101 Prostate cancer (hormone-refractory) - docetaxel: analysis of cost impact Management of hormone-refractory prostate cancer, from the Management of hormone-refractory prostate cancer, from Prostate Cancer Infolink web site, preserved at Phoenix5. Hormone Refractory Prostate Cancer - hrpca.org For those men facing hormone refractory prostate cancer. This is a support group for HRPC issues only. Hormone-Refractory Prostate Cancer with Bone Metastases - Prostate Newer Concepts in the Treatment of Hormone-Refractory Prostate Cancer with Bone Metastases: Combinations of Bone-Seeking Radiopharmaceuticals and |
| hormonal refractory prostate cancer |
|
prostate cancer 26 psa level location massage prostate va operation procedure prostate prostate cancer alternative treatment |